Accrued Expenses

9 Months Ended

Sep. 30, 2018

8.	ACCRUED EXPENSES

Accrued expenses consisted of the following:

	September 30, 2018		December 31, 2017

Accrued clinical operations and trials costs	$	4,223,787	$	2,003,799
Accrued product development costs		1,333,392		1,255,439
Accrued compensation		1,504,736		1,335,672
Accrued other		323,681		146,609
Total	$	7,385,596	$	4,741,519